TY - JOUR
T1 - Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease
AU - Nitschke, Felix
AU - Sullivan, Mitchell A.
AU - Wang, Peixiang
AU - Zhao, Xiaochu
AU - Chown, Erin E.
AU - Perri, Ami M.
AU - Israelian, Lori
AU - Juana-López, Lucia
AU - Bovolenta, Paola
AU - Rodríguez de Córdoba, Santiago
AU - Steup, Martin
AU - Minassian, Berge A.
N1 - Funding Information:
This work was supported by families and friends of the Chelsea's Hope Lafora Disease Research Fund, Associazione Italiana Lafora (AILA), France-Lafora, the Milana and Tatjana Gajic Lafora Disease Foundation, Genome Canada, the Ontario Brain Institute (OBI) and The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) under award number P01 NS097197. Mitchell A. Sullivan was supported by an NHMRC CJ Martin Fellowship (GNT1092451). BA Minassian holds the University of Toronto Michael Bahen Chair in Epilepsy Research and the University of Texas Southwestern UTSW Jimmy Elizabeth Westcott Distinguished Chair in Pediatric Neurology. We wish to thank Drs. Gino Cingolani (Thomas Jefferson University, Philadelphia, USA), and Michael Emes and Ian Tetlow (University of Guelph, Canada) for insightful discussions and the latter two for facilitating the use of the HPAEC-PAD equipment.
Publisher Copyright:
© 2017 The Authors. Published under the terms of the CC BY 4.0 license
PY - 2017/7
Y1 - 2017/7
N2 - Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss-of-function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphorylated and poorly hydrosoluble. It precipitates and accumulates into neurotoxic Lafora bodies (LBs). The leading LD hypothesis that hyperphosphorylation causes the insolubility was recently challenged by the observation that phosphatase-inactive laforin rescues the laforin-deficient LD mouse model, apparently through correction of a general autophagy impairment. We were for the first time able to quantify brain glycogen phosphate. We also measured glycogen content and chain lengths, LBs, and autophagy markers in several laforin- or malin-deficient mouse lines expressing phosphatase-inactive laforin. We find that: (i) in laforin-deficient mice, phosphatase-inactive laforin corrects glycogen chain lengths, and not hyperphosphorylation, which leads to correction of glycogen amounts and prevention of LBs; (ii) in malin-deficient mice, phosphatase-inactive laforin confers no correction; (iii) general impairment of autophagy is not necessary in LD. We conclude that laforin's principle function is to control glycogen chain lengths, in a malin-dependent fashion, and that loss of this control underlies LD.
AB - Lafora disease (LD) is a fatal progressive epilepsy essentially caused by loss-of-function mutations in the glycogen phosphatase laforin or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphorylated and poorly hydrosoluble. It precipitates and accumulates into neurotoxic Lafora bodies (LBs). The leading LD hypothesis that hyperphosphorylation causes the insolubility was recently challenged by the observation that phosphatase-inactive laforin rescues the laforin-deficient LD mouse model, apparently through correction of a general autophagy impairment. We were for the first time able to quantify brain glycogen phosphate. We also measured glycogen content and chain lengths, LBs, and autophagy markers in several laforin- or malin-deficient mouse lines expressing phosphatase-inactive laforin. We find that: (i) in laforin-deficient mice, phosphatase-inactive laforin corrects glycogen chain lengths, and not hyperphosphorylation, which leads to correction of glycogen amounts and prevention of LBs; (ii) in malin-deficient mice, phosphatase-inactive laforin confers no correction; (iii) general impairment of autophagy is not necessary in LD. We conclude that laforin's principle function is to control glycogen chain lengths, in a malin-dependent fashion, and that loss of this control underlies LD.
KW - Lafora disease
KW - glycogen chain length
KW - glycogen phosphorylation
KW - laforin
KW - malin
UR - http://www.scopus.com/inward/record.url?scp=85019575154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019575154&partnerID=8YFLogxK
U2 - 10.15252/emmm.201707608
DO - 10.15252/emmm.201707608
M3 - Article
C2 - 28536304
AN - SCOPUS:85019575154
SN - 1757-4676
VL - 9
SP - 906
EP - 917
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 7
ER -